Stay updated on Pembrolizumab Combo in ES-SCLC 2nd-line Therapy Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab Combo in ES-SCLC 2nd-line Therapy Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab Combo in ES-SCLC 2nd-line Therapy Clinical Trial page

  1. Check
    5 days ago
    No Change Detected
  2. Check
    12 days ago
    Change Detected
    Summary
    The page now shows the study as Active, not recruiting; it adds widened ILD/history exclusions and specifies contraception durations for R-Dx-d as 150 days during treatment and 210 days after the last dose.
    Difference
    0.6%
    Check dated 2026-05-18T03:48:48.000Z thumbnail image
  3. Check
    19 days ago
    No Change Detected
  4. Check
    27 days ago
    No Change Detected
  5. Check
    34 days ago
    Change Detected
    Summary
    ClinicalTrials.gov’s page software revision label was updated from v3.5.2 to v3.5.3, indicating a minor platform/version maintenance change.
    Difference
    0.0%
    Check dated 2026-04-26T08:24:45.000Z thumbnail image
  6. Check
    41 days ago
    Change Detected
    Summary
    Recruitment status updated to Completed on 2026-04-13. The revision was updated to v3.5.2, replacing the earlier v3.5.0 entry.
    Difference
    0.3%
    Check dated 2026-04-19T01:37:52.000Z thumbnail image
  7. Check
    70 days ago
    Change Detected
    Summary
    Revision: v3.5.0 was added. Date stamps include 2026-03-18, 2026-03-19, and 2026-03, along with the future date 2029-12-10.
    Difference
    0.2%
    Check dated 2026-03-21T08:51:24.000Z thumbnail image
  8. Check
    85 days ago
    Change Detected
    Summary
    Page revision updated from v3.4.2 to v3.4.3.
    Difference
    0.0%
    Check dated 2026-03-06T20:21:18.000Z thumbnail image
  9. Check
    106 days ago
    Change Detected
    Summary
    The page shows a new status: Active, not recruiting, and the revision version was updated to v3.4.2. Additionally, a contact phone number and the Recruiting label were removed.
    Difference
    0.3%
    Check dated 2026-02-13T11:47:51.000Z thumbnail image

Stay in the know with updates to Pembrolizumab Combo in ES-SCLC 2nd-line Therapy Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in ES-SCLC 2nd-line Therapy Clinical Trial page.